GlassScriptPhysician profile
Kala Grant
NPI 1295366987
$980.87
in general payments reported to CMS, 2019-2025
22 companies · $658 in 2025
The $658 reported for 2025 was more than what 80% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $81.78 · 2022: $24.51 · 2023: $17.85 · 2024: $199 · 2025: $658.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $875.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $874.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $138.92 | 2025 | Ozempic, Wegovy, Rybelsus |
| Abbott Laboratories | $115.11 | 2025 | Freestyle Libre 3 |
| Abbvie INC. | $62.91 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $61.17 | 2024-2025 | Farxiga, Airsupra |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $57.68 | 2024 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.70 | 2024-2025 | Jardiance |
| Glaxosmithkline, LLC. | $56.15 | 2021-2023 | Bexsero, Pediarix |
| Bayer Healthcare Pharmaceuticals INC. | $50.67 | 2024-2025 | |
| Lundbeck LLC | $46.54 | 2025 | Vyepti |
| Merck Sharp & Dohme LLC | $43.66 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Sumitomo Pharma America, INC. | $37.39 | 2025 | Gemtesa |
| Lilly USA, LLC | $37.18 | 2025 | Jardiance, Mounjaro, Zepbound |
| Medtronic, INC. | $34.91 | 2025 | Inceptiv, Minimed 780g |
| Takeda Pharmaceuticals U.S.A., INC. | $33.84 | 2021 | |
| Amgen INC. | $33.61 | 2024-2025 | Krystexxa, Repatha, Otezla |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tonix Medicines, INC. | $20.11 | 2025 | Tonmya |
| Esperion Therapeutics, INC. | $18.93 | 2025 | Nexletol |
| Supernus Pharmaceuticals, INC. | $17.81 | 2021 | |
| Pfizer INC. | $16.73 | 2025 | |
| Tris Pharma INC | $16.34 | 2021 | |
| Mylan Specialty L.P. | $16.15 | 2024 | Yupelri |
| Phathom Pharmaceuticals, INC. | $8.36 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kala Grant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.